Merck & Co. Stock News

Pfizer has at least two key candidates in the pipeline that look like future winners. Merck has launched several products in preparation for a massive upcoming patent cliff.

Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans.

Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug prices to cheaper ones abroad. Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk have already struck deals with the Trump administration to cut prices.

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.

Merck is reiterated as a buy, with the price target raised to $114, reflecting robust Q3 results and strong technical momentum. Q3 saw non-GAAP EPS of $2.58 (vs. $2.35 consensus) and revenue of $17.3B, driven by Keytruda, Gardasil, and disciplined cost management. Pipeline strength, including 80 Phase III trials and the Verona Pharma acquisition, positions MRK for growth beyond Keytruda's paten...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with multibillion-dollar potential, according to internal documents seen by Reuters.

Pfizer has a substantial 6.6% dividend yield but a payout ratio exceeding 100%. Eli Lilly has a payout ratio of roughly 30%, but its dividend yield is a tiny 0.6%.